Research and clinical trials

The study identifies a specific bacterial protein region (flagellin epitope) that many Crohn’s patients make antibodies to, which could help diagnose disease and predict who may develop complications.

Diet is a modifiable factor that may influence inflammation and the gut microbiome. If the Mediterranean diet is linked with lower disease activity and inflammatory markers in newly diagnosed Crohn’s disease, patients...

Based on the title and source metadata, this appears to be a clinical study related to Research and clinical trials. The original article is from msn.com.

Cure8 could only read part of this source from healthcentral.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Crohn's disease, and Ulcerative colitis.

Fundraising events support IBD research, programs and patient services. Money raised can contribute to work on personalized treatments and diagnostic tools that might benefit people with Crohn’s disease or ulcerative...

A newly approved biologic, Omvoh (mirikizumab), gives another FDA‑approved treatment option for adults with moderate to severe Crohn’s disease and adds to Lilly’s role in IBD care.

Based on the title and source metadata, this appears to be a basic science related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from jewishpress.com.

Cure8 could only read part of this source from morningstar.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Crohn's disease, and Research and clinical...

The article reports regulatory approvals and clinical-trial results for Omvoh (mirikizumab), which could offer a new option for people with moderate–severe Crohn’s who still have disruptive symptoms like bowel urgency....

Cure8 could only read part of this source from whatech.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease and Research and clinical trials.

Based on the title and source metadata, this appears to be a biomarker study related to Crohn's disease, Inflammatory bowel disease, and Biomarker. The original article is from firstwordpharma.com.

The article spotlights duvakitug and the anti‑TL1A drug class as potential new options for ulcerative colitis and Crohn’s disease, especially for treatment‑experienced patients. Biomarker‑driven studies could help...

This article reports positive trial results for ustekinumab, a drug that targets IL-12 and IL-23, showing benefit in people with Crohn's disease who did not respond to anti‑TNF drugs. That could expand options for...

This paper highlights potential ubiquitination-related genes and immune-cell patterns that could help researchers understand Crohn’s disease biology and point to new targets for lab validation. For patients, it signals...

Based on the title and source metadata, this appears to be a market or business news related to Inflammatory bowel disease, Crohn's disease, and Research and clinical trials. The original article is from...

A pipeline overview can indicate which new drugs and trials might affect future treatment options for Crohn’s disease. Patients on biologics or those with treatment-refractory disease may see new options under study that...

The event raised funds for the Crohn’s & Colitis Foundation, which supports IBD research, education, and patient care. Community fundraising events can expand local support networks and resources for people living with...

This study suggests a Crohn's genetic risk factor can change pregnancy-related gut microbiome shifts and increase inflammatory signals in mice — which could help researchers look for microbial biomarkers that predict...

If you have Crohn’s disease, this study suggests following a Mediterranean-style diet may be linked with lower inflammation and a gentler disease course, and it could positively change the gut microbiome and metabolites.

Based on the title and source metadata, this appears to be a biomarker study related to Crohn's disease, Inflammatory bowel disease, and Biomarker. The original article is from generalsurgerynews.com.

This article is a market research summary about the global Crohn’s disease treatment market — it describes sales forecasts, industry players, and market trends rather than new clinical findings or patient-focused...

A study aiming to identify who is likely to develop Crohn’s disease and to test preventing it could eventually allow truly early treatment before symptoms begin. If successful, validated biomarkers and a risk score could...

Cure8 could only read part of this source from patientcareonline.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Biomarker.

Researchers are trying to find blood biomarkers and a risk score that could predict who will develop Crohn’s disease before symptoms appear, which might enable earlier interventions or prevention in the future.

People with celiac disease may have higher risks for several digestive cancers and for inflammatory bowel diseases (Crohn’s and UC) according to this large French cohort study. Knowing these associations can help...

If successful, validated biomarkers and a blood risk score could allow clinicians to identify people at high risk of developing Crohn's disease and eventually test interventions to prevent symptoms. Prevention-focused...

This project aims to detect Crohn’s before symptoms appear and test preventive treatment—research that could change diagnosis and care for people with family risk. Successful biomarkers could allow earlier monitoring or...

The study suggests a possible link between psoriasis, leaky gut, and Crohn’s disease—topics that could help explain why some people with psoriasis report more gut problems. People with psoriasis or IBD may find the...

This study links a specific SERPINB4 gene mutation to impaired intestinal epithelial cell function in twins with Crohn’s disease, which could help explain how rare genetic variants contribute to disease in some patients.

This gives adults with moderately to severely active Crohn’s disease another FDA‑approved biologic option, including for people who did not respond to or could not tolerate other therapies.

Cure8 found this source from medindia.net, but the page could not be read reliably yet. It is tagged for Research and clinical trials. Open the original article for the full details.

Based on the title and source metadata, this appears to be an observational study related to Research and clinical trials. The original article is from msn.com.

Based on the title and source metadata, this appears to be a clinical study related to Research and clinical trials. The original article is from msn.com.

Based on the title and source metadata, this appears to be an observational study related to Research and clinical trials. The original article is from msn.com.

Based on the title and source metadata, this appears to be a fda approval related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from msn.com.

A new FDA approval expands treatment options for adults with moderate-to-severe Crohn's disease and means mirikizumab (Omvoh) is now approved for both Crohn's disease and ulcerative colitis. The decision was based on...

Based on the title and source metadata, this appears to be a fda approval related to Crohn's disease, Mirikizumab, and IL-23 inhibitor. The original article is from gastroendonews.com.

Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab. Open the original article for the...

This approval adds a newly authorized biologic option (mirikizumab/Omvoh) for adults with moderate-to-severe Crohn disease, including people who have not done well on steroids, immunomodulators, or prior biologics.

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Medications. Open the original article for the full details.

A new FDA approval means another biologic option for people with moderately to severely active Crohn’s disease, including patients who have failed or not tolerated prior therapies.

This announces a new FDA‑approved treatment (mirikizumab/Omvoh) for adults with moderately to severely active Crohn disease, offering another option for people who haven’t responded to prior therapies. The approval was...

A new FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderate-to-severe Crohn disease another treatment option with one-year trial data showing improved clinical remission and endoscopic healing versus...

An FDA approval means another biologic option is available for Crohn’s disease, which could affect treatment choices and insurance coverage. The approval also signals pharma competition and pipeline activity that may...

An FDA approval means Omvoh is now an available biologic option for adults with Crohn’s disease, potentially expanding treatment choices. Payer decisions mentioned in the article could affect how quickly patients can...

This gives adults with moderately to severely active Crohn’s disease an additional FDA-approved biologic option that targets the IL-23 pathway. Approval was supported by late-stage trial results showing improvements in...

A new FDA-approved treatment option is now available for adults with moderately to severely active Crohn’s disease, including people who’ve not responded to or tolerated prior therapies. Approval was supported by phase 3...

A new FDA-approved biologic option (Omvoh/mirikizumab) is now available for adults with moderately to severely active Crohn’s disease, potentially expanding treatment choices.